As of 2025-05-22, the EV/EBITDA ratio of Ascletis Pharma Inc (1672.HK) is -17.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 1672.HK's latest enterprise value is 5,817.49 mil HKD. 1672.HK's TTM EBITDA according to its financial statements is -323.29 mil HKD. Dividing these 2 quantities gives us the above 1672.HK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 24.1x - 29.1x | 27.4x |
| Forward P/E multiples | 8.7x - 13.7x | 9.7x |
| Fair Price | (7.81) - (4.02) | (5.78) |
| Upside | -211.6% - -157.5% | -182.5% |
| Date | EV/EBITDA |
| 2025-05-22 | -139.70 |
| 2025-05-21 | -147.87 |
| 2025-05-20 | -132.82 |
| 2025-05-19 | -118.62 |
| 2025-05-16 | -115.18 |
| 2025-05-15 | -126.80 |
| 2025-05-14 | -122.71 |
| 2025-05-13 | -130.45 |
| 2025-05-12 | -127.01 |
| 2025-05-09 | -139.48 |
| 2025-05-08 | -140.77 |
| 2025-05-07 | -133.46 |
| 2025-05-06 | -138.84 |
| 2025-05-02 | -138.19 |
| 2025-04-30 | -133.89 |
| 2025-04-29 | -140.99 |
| 2025-04-28 | -130.24 |
| 2025-04-25 | -132.39 |
| 2025-04-24 | -142.06 |
| 2025-04-23 | -135.61 |
| 2025-04-22 | -129.59 |
| 2025-04-17 | -103.57 |
| 2025-04-16 | -108.73 |
| 2025-04-15 | -131.74 |
| 2025-04-14 | -121.42 |
| 2025-04-11 | -112.60 |
| 2025-04-10 | -100.99 |
| 2025-04-09 | -103.14 |
| 2025-04-08 | -107.01 |
| 2025-04-07 | -103.79 |
| 2025-04-03 | -137.12 |
| 2025-04-02 | -162.06 |
| 2025-04-01 | -182.92 |
| 2025-03-31 | -171.09 |
| 2025-03-28 | -157.54 |
| 2025-03-27 | -159.05 |
| 2025-03-26 | -177.54 |
| 2025-03-25 | -184.42 |
| 2025-03-24 | -195.17 |
| 2025-03-21 | -174.75 |
| 2025-03-20 | -196.03 |
| 2025-03-19 | -181.41 |
| 2025-03-18 | -173.24 |
| 2025-03-17 | -165.50 |
| 2025-03-14 | -167.65 |
| 2025-03-13 | -159.91 |
| 2025-03-12 | -165.07 |
| 2025-03-11 | -155.39 |
| 2025-03-10 | -153.24 |
| 2025-03-07 | -145.72 |